Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Madurella mycetomatis sequenced strains

ABSTRACT: The combination of manogepix and itraconazole is synergistic and inhibits the growth of Madurella mycetomatis

PROVIDER: PRJEB62822 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Madurella mycetomatis

Project description:Madurella mycetomatis Genome sequencing and assembly

| PRJNA579746 | ENA

Madurella mycetomatis

Project description:Genomics of Madurella mycetomatis in Sudan

| PRJNA779095 | ENA

Madurella mycetomatis strain:mm55

Project description:Madurella mycetomatis strain:mm55 Genome sequencing and assembly

| PRJNA267680 | ENA

Genome-wide mapping of the Galleria mellonella larvae transcription start sites during infection with the madurella mycetomatis pathogen

Project description:Using Low Quantity single strand CAGE (LQ-ssCAGE) we mapped the transcription start sites (TSS) and annotated the 5' end of the invertebrate Galleria mellonella which is upcoming and booming in the last years as an experimental model in infection disease and immunology research. The current genome annotation of this model lacks the annotation of the 5' end and TSS information. To map TSS under healthy and infection conditions, the G. mellonella larva was infected with the fungal pathogen Madurella mycetomatis After 4, 30 and 52 hours of the infection, larvae were treated with itraconazole or ravuconazole. RNA-seq and LQ-ssCAGE libraries prepared and sequenced. The LQ-ssCAGE data was processed to identify CAGE transcription start site (CTSS), uni- and bi-directional clusters. LQ-ssCAGE enabled us to precisely identify (39,410) TSS and (249) active enhancers. We assigned genomic features to the resulting TSSs and enhancers. The majority of the TSS peaks are annotated as promoter regions while the enhancers were annotated as intergenic and genic. Furthermore, we confirmed the quality of TSS by promoter shapes and GC bias. We identified a set of super-enhancers and predicted de-novo motifs. In this study we reported the first atlas of TSS and active enhancers of the G. mellonella.

2024-12-11 | GSE282923 | GEO

Proteomic analysis of the processes leading to Madurella mycetomatis grain formation in Galleria mellonella larvae

Project description:Mycetoma is a neglected chronic and granulomatous infection primarily associated with the fungal pathogen Madurella mycetomatis. Infection is characterised by the formation of fungal grains inside the infected tissue which commonly result in severe deformity and disability. Currently the biochemical processes and interactions between host and pathogen which result in grain formation are unknown. Furthermore, the infection process in mammals takes months to fully develop. In order to unravel these processes Galleria mellonella larvae were infected with M. mycetomatis and hyphae and grain formation, survival, fungal burden and proteomic responses of larvae were monitored for 10 days. At 24 h post infection proteins indicative of muscle invasion and humoral immune response activation were enriched in infected larval hemolymph. By 72 h immune related hdd11 was increased 337 fold, heat shock proteins 90 was increased 40 fold and glutathione-S-transferase was increased 25 fold. By 7 days post infection proteins which were associated with grain formation (hdd11 [533 fold], hemocentin [54 fold]) and a range of antimicrobial peptides were enriched. During the 7 day period a variety of proteins were decreased in infected hemolymph (e.g. hexamerin, apolipophorin and cationic peptide CP8). This data also identified 75 M. mycetomatis proteins released into hemolymph during infection. Proteins were also extracted from M. mycetomatis grains taken from larvae infected for 24, 72 and 7 days. These proteins give an insight into the interactions between the larval immune response and M. mycetomatis at the cellular levels during infection. These results identify similarities between the infection processes of M. mycetomatis in G. mellonella larvae and in humans and identify novel proteins from M. mycetomatis which may play a crucial role in grain development.

2020-03-19 | PXD013532 | Pride

Mycetoma due to Madurella mycetomatis.

Project description:Mycetoma is a progressive destructive disease causing severe disability, if untreated, in otherwise healthy people. Susceptible populations are usually adult males and disease is characterized by the triad of tumor formation, presence of grains and draining sinuses. Here, we report a case of mycetoma of a young female, manifested only as a painful swelling over left ankle which was initially suspected as a malignancy. The preliminary diagnosis of mycetoma came with the presence of characteristic "dot in circle" sign in radiological evaluation which was confirmed by the positive fungal culture of 2nd biopsy for M. mycetomatis.

| S-EPMC7283137 | biostudies-literature

Madurella fahalii

Project description:Madurella fahalii overview

| PRJNA1162630 | ENA

Madurella mycetomatis

Project description:One of the major causative agents of mycetoma

| PRJNA172526 | ENA

Genome-wide mapping of the Galleria mellonella larvae transcription start sites during infection with the madurella mycetomatis pathogen

Project description:Genome-wide mapping of the Galleria mellonella larvae transcription start sites during infection with the madurella mycetomatis pathogen

| PRJNA1191010 | ENA

In vitro antifungal activity of isavuconazole against Madurella mycetomatis.

Project description:Currently, therapy of black-grain mycetoma caused by Madurella mycetomatis consists of extensive debridement of the infected tissue combined with prolonged antifungal therapy with ketoconazole or itraconazole. In the present study, the in vitro activity of the new triazole isavuconazole toward M. mycetomatis was evaluated. Isavuconazole appeared to have high activity against M. mycetomatis, with MICs ranging from ?0.016 to 0.125 ?g/ml. Due to its favorable pharmacokinetics, isavuconazole could be a promising antifungal agent in the treatment of mycetoma.

| S-EPMC3486573 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data